130 related articles for article (PubMed ID: 26852973)
1. Re: Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
Taneja SS
J Urol; 2016 Feb; 195(2):350. PubMed ID: 26852973
[No Abstract] [Full Text] [Related]
2. Survival with Newly Diagnosed Metastatic Prostate Cancer in the "Docetaxel Era": Data from 917 Patients in the Control Arm of the STAMPEDE Trial (MRC PR08, CRUK/06/019).
James ND; Spears MR; Clarke NW; Dearnaley DP; De Bono JS; Gale J; Hetherington J; Hoskin PJ; Jones RJ; Laing R; Lester JF; McLaren D; Parker CC; Parmar MKB; Ritchie AWS; Russell JM; Strebel RT; Thalmann GN; Mason MD; Sydes MR
Eur Urol; 2015 Jun; 67(6):1028-1038. PubMed ID: 25301760
[TBL] [Abstract][Full Text] [Related]
3. Observed Advantages of the STAMPEDE Study Design.
Scher HI
Eur Urol; 2015 Jun; 67(6):1039-1041. PubMed ID: 25544634
[No Abstract] [Full Text] [Related]
4. Chemotherapy at First Diagnosis of Advanced Prostate Cancer - Revolution or Evolution? Findings from a British Uro-oncology Group UK Survey to Evaluate Oncologists' Views on First-line Docetaxel in Combination with Androgen Deprivation Therapy in Castrate-sensitive Metastatic and High-risk/Locally Advanced Prostate Cancer.
Davda R; Hughes S; Jones R; Crabb SJ; Troup J; Payne H
Clin Oncol (R Coll Radiol); 2016 Jun; 28(6):376-85. PubMed ID: 26874654
[TBL] [Abstract][Full Text] [Related]
5. Irrefutable evidence for the use of docetaxel in newly diagnosed metastatic prostate cancer: results from the STAMPEDE and CHAARTED trials.
van Soest RJ; de Wit R
BMC Med; 2015 Dec; 13():304. PubMed ID: 26695172
[TBL] [Abstract][Full Text] [Related]
6. Docetaxel for hormone-sensitive metastatic prostate cancer.
Baker H
Lancet Oncol; 2015 Sep; 16(9):e432. PubMed ID: 26278160
[No Abstract] [Full Text] [Related]
7. Should docetaxel be administered earlier in prostate cancer therapy?
Graff JN; Beer TM
Expert Rev Anticancer Ther; 2015; 15(9):977-9. PubMed ID: 26223224
[TBL] [Abstract][Full Text] [Related]
8. [Docetaxel for metastatic prostate cancer: early is better].
Gietema JA; Oosting SF
Ned Tijdschr Geneeskd; 2016; 160():D215. PubMed ID: 27405569
[TBL] [Abstract][Full Text] [Related]
9. Chemotherapy for metastatic castrate-sensitive prostate cancer.
Miller RE; Sweeney CJ
Prostate Cancer Prostatic Dis; 2016 Jun; 19(2):139-44. PubMed ID: 26976365
[TBL] [Abstract][Full Text] [Related]
10. Management of metastatic prostate cancer in the elderly: identifying fitness for chemotherapy in the post-STAMPEDE world.
Thompson AL; Sarmah P; Beresford MJ; Jefferies ER
BJU Int; 2017 Dec; 120(6):751-754. PubMed ID: 28834013
[No Abstract] [Full Text] [Related]
11. Re: Androgen-deprivation therapy alone or with docetaxel in non-castrate metastatic prostate cancer (GETUG-AFU 15): a randomised, open-label, phase 3 trial.
Taneja SS
J Urol; 2013 Dec; 190(6):2094. PubMed ID: 24209521
[No Abstract] [Full Text] [Related]
12. Docetaxel in hormone-sensitive advanced prostate cancer; GENESIS-SEFH evaluation reporta.
García de Paredes Esteban JC; Alegre Del Rey EJ; Asensi Díez R
Farm Hosp; 2017 Jul; 41(4):550-558. PubMed ID: 28683707
[TBL] [Abstract][Full Text] [Related]
13. Abiraterone and increased survival in metastatic prostate cancer.
Sonpavde G
N Engl J Med; 2011 Aug; 365(8):766-7; author reply 767-8. PubMed ID: 21864181
[No Abstract] [Full Text] [Related]
14. Will chemotherapy change the management of prostate cancer?
Gilson C; Sydes MR; Chowdhury S
BJU Int; 2016 Aug; 118(2):190-2. PubMed ID: 26696125
[No Abstract] [Full Text] [Related]
15. 'Charting a new course for prostate cancer' - currying favor for docetaxel in hormone-sensitive metastatic prostate cancer.
Voskoboynik M; Staffurth J; Malik Z; Sweeney C; Chowdhury S
Expert Rev Anticancer Ther; 2014 Nov; 14(11):1253-6. PubMed ID: 25353342
[TBL] [Abstract][Full Text] [Related]
16. Issues in applying multi-arm multi-stage methodology to a clinical trial in prostate cancer: the MRC STAMPEDE trial.
Sydes MR; Parmar MK; James ND; Clarke NW; Dearnaley DP; Mason MD; Morgan RC; Sanders K; Royston P
Trials; 2009 Jun; 10():39. PubMed ID: 19519885
[TBL] [Abstract][Full Text] [Related]
17. Q-TWiST analysis of patients with metastatic castrate naive prostate cancer treated by androgen deprivation therapy with or without docetaxel in the randomised phase III GETUG-AFU 15 trial.
Marino P; Sfumato P; Joly F; Fizazi K; Oudard S; Culine S; Habibian M; Boher JM; Gravis G
Eur J Cancer; 2017 Oct; 84():27-33. PubMed ID: 28780479
[TBL] [Abstract][Full Text] [Related]
18. [Addition of docetaxel to hormonal therapy in low- and high-burden metastatic hormone sensitive prostate cancer: long-term survival results from the STAMPEDE trial].
von Amsberg G
Urologe A; 2020 Jun; 59(6):723-724. PubMed ID: 32240319
[No Abstract] [Full Text] [Related]
19. The Role of Docetaxel in Non-Castrate Resistant Metastatic Prostate Cancer: An Evidence-based Case Report.
Rahman F; Rahardjo HE; Ariwicaksono SC; Hafizar H; Sembiring MGA; Andika R; Patandung R; Hidianingsih S; Hotasi SL
Acta Med Indones; 2017 Jan; 49(1):74-78. PubMed ID: 28450658
[TBL] [Abstract][Full Text] [Related]
20. Re: Chemohormonal Therapy in Metastatic Hormone-Sensitive Prostate Cancer.
Taneja SS
J Urol; 2016 Jan; 195(1):94. PubMed ID: 26699961
[No Abstract] [Full Text] [Related]
[Next] [New Search]
